| Literature DB >> 33306946 |
James C Doidge1, Doug W Gould1, Paloma Ferrando-Vivas1, Paul R Mouncey1, Karen Thomas1, Manu Shankar-Hari2,3, David A Harrison1, Kathryn M Rowan1.
Abstract
Rationale: By describing trends in intensive care for patients with coronavirus disease (COVID-19) we aim to support clinical learning, service planning, and hypothesis generation.Entities:
Keywords: COVID-19; United Kingdom; intensive care; mortality; trends
Mesh:
Year: 2021 PMID: 33306946 PMCID: PMC7924583 DOI: 10.1164/rccm.202008-3212OC
Source DB: PubMed Journal: Am J Respir Crit Care Med ISSN: 1073-449X Impact factor: 21.405
Figure 1.Coronavirus disease (COVID-19) critical care admission rates. (A) New ICU admissions, transfers and readmissions, and patients remaining in the ICU all contribute to the total number of patients in the ICU. (B) Regions are the National Health Service–commissioning regions, denominators are Office for National Statistics estimates of the mid-2019 regional population aged 15 years and over (13), and moving averages are linearly weighted averages ± 7 days.
Figure 2.Trends in characteristics of patients with coronavirus disease (COVID-19) on admission to ICUs. The lines are the moving averages and linearly weighted averages ± 7 days. Patients first admitted during February or July are not presented because of the small numbers. BMI = body mass index; CI = confidence interval.
Figure 4.Trends in the coronavirus disease (COVID-19) processes of care in ICUs and outcomes. The lines are moving averages and linearly weighted averages ± 7 days. Patients first admitted during February or July were not shown because of the small numbers. The durations are capped and stratified by survivorship at 28 days. CI = confidence interval.
COVID-19 Cohort by Time Period
| Characteristic | Median (IQR) or | Unadjusted Difference (95% CI) | |||
|---|---|---|---|---|---|
| Prepeak Period from February 1 to March 28 | Peak Period from March 29 to April 12 | Postpeak Period from April 13 to July 31 | Peak vs. Prepeak Periods | Postpeak vs. Prepeak Periods | |
| 2,451 | 4,624 | 3,666 | — | — | |
| Mean new admissions/d per hospital, median (IQR) | 0.3 (0.1 to 0.6) | 1.1 (0.6 to 1.9) | 0.1 (0.1 to 0.2) | −0.1 (−0.2 to −0.1) | |
| Patient characteristics on admission to ICU | | ||||
| Age | |||||
| Median (IQR) | 61 (51 to 70) | 59 (51 to 67) | 59 (50 to 68) | ||
| ≥75 yr, | 329/2,451 (13.4%) | 372/4,624 (8.0%) | 381/3,666 (10.4%) | ||
| Sex, M, | 1,778/2,449 (72.6%) | 3,321/4,621 (71.9%) | 2,432/3,665 (66.4%) | −0.7% (−2.9% to 1.5%) | |
| Ethnic group, | |||||
| Asian | 312/2,347 (13.3%) | 729/4,461 (16.3%) | 587/3,530 (16.6%) | ||
| Black | 303/2,347 (12.9%) | 427/4,461 (9.6%) | 258/3,530 (7.3%) | ||
| White | 1,532/2,347 (65.3%) | 2,895/4,461 (64.9%) | 2,420/3,530 (68.6%) | −0.4% (−2.8% to 2.0%) | |
| Other | 200/2,347 (8.5%) | 410/4,461 (9.2%) | 265/3,530 (7.5%) | 0.7% (−0.7% to 2.1%) | −1.0% (−2.4% to 0.4%) |
| Any prior dependency, | 242/2,436 (9.9%) | 360/4,568 (7.9%) | 516/3,634 (14.2%) | ||
| Any severe comorbidities, | 168/2,437 (6.9%) | 302/4,568 (6.6%) | 408/3,638 (11.2%) | −0.3% (−1.5% to 1.0%) | |
| Most deprived quintile, | 498/2,419 (20.6%) | 1,154/4,563 (25.3%) | 1,071/3,611 (29.7%) | ||
| Body mass index, kg/m2 | |||||
| Median (IQR) | 28.0 (24.8 to 32.7) | 28.4 (25.0 to 32.9) | 28.1 (24.6 to 33.3) | 0.1 (−0.3 to 0.5) | |
| ≥30, | 887/2,358 (37.6%) | 1,758/4,371 (40.2%) | 1,374/3,472 (39.6%) | 2.0% (−0.6% to 4.5%) | |
| CPR within or before 24 h, | 24/2,451 (1.0%) | 47/4,621 (1.0%) | 53/3,665 (1.4%) | 0.0% (−0.4% to 0.5%) | 0.5% (−0.1% to 1.0%) |
| Hospital stay before ICU admission | |||||
| Duration (calendar days), mean (SD) | 1.8 (6.2) | 1.9 (3.8) | 3.6 (8.1) | 0.1 (−0.1 to 0.4) | |
| Admitted to ICU on same day as hospital, | 1,162/2,451 (47.4%) | 1,909/4,624 (41.3%) | 1,297/3,666 (35.4%) | ||
| First-24-h physiology in ICU | | ||||
| PaO2/F | |||||
| Median (IQR) | 126.0 (87.9 to 173.6) | 115.5 (84.6 to 159.0) | 116.7 (82.5 to 173.6) | ||
| ≤200 mm Hg, | 1,972/2,367 (83.3%) | 3,829/4,353 (88.0%) | 2,746/3,389 (81.0%) | ||
| Acute renal failure (KDIGO stage 2 or 3), | 1,082/2,416 (44.8%) | 2,356/4,518 (52.1%) | 1,563/3,578 (43.7%) | −1.1% (−3.7% to 1.5%) | |
| APACHE II score | |||||
| Acute physiology score, median (IQR) | 11 (9, 14) | 11 (8, 14) | 11 (9, 14) | 0.0 (0.0 to 0.0) | 0.0 (−0.5 to 0.5) |
| Acute physiology score ≥ 14, | 686/2,441 (28.1%) | 1,225/4,589 (26.7%) | 1,166/3,645 (32.0%) | −1.4% (−3.6% to 0.8%) | |
| APACHE II score, median (IQR) | 15 (12 to 18) | 14 (11 to 18) | 15 (12 to 19) | 0.0 (−0.5 to 0.5) | |
| APACHE II score ≥ 18, | 706/2,441 (28.9%) | 1,182/4,588 (25.8%) | 1,161/3,645 (31.9%) | ||
| Processes of care in ICU | | ||||
| Invasive ventilation | |||||
| During first 24 h, | 1,825/2,423 (75.3%) | 2,839/4,560 (62.3%) | 1,541/3,616 (42.6%) | ||
| At any point, | 2,083/2,451 (85.0%) | 3,591/4,623 (77.7%) | 2,238/3,662 (61.1%) | ||
| Duration (calendar days) among survivors, mean (SD) | 17.3 (9.1) | 19.2 (8.9) | 18.4 (9.4) | ||
| Duration (calendar days) among nonsurvivors, mean (SD) | 10.6 (6.1) | 10.7 (6.6) | 10.3 (7.1) | 0.1 (−0.4 to 0.6) | −0.3 (−0.9 to 0.3) |
| Renal replacement | |||||
| At any point, | 771/2,451 (31.5%) | 1,269/4,622 (27.5%) | 844/3,660 (23.1%) | ||
| Duration (calendar days) among survivors, mean (SD) | 13.4 (8.3) | 14.5 (9.2) | 13.5 (9.7) | 1.1 (0.0 to 2.2) | 0.1 (−1.2 to 1.3) |
| Duration (calendar days) among nonsurvivors, mean (SD) | 6.5 (4.8) | 6.9 (5.3) | 6.7 (5.1) | 0.4 (−0.2 to 1.1) | 0.2 (−0.5 to 0.9) |
| Outcomes | | ||||
| 28-d in-hospital mortality, | 1,068/2,450 (43.6%) | 1,911/4,620 (41.4%) | 1,227/3,649 (33.6%) | −2.2% (−4.7% to 0.2%) | |
| ICU stay | |||||
| Duration (calendar days) overall, mean (SD) | 13.5 (9.2) | 13.6 (9.6) | 12.4 (9.7) | 0.1 (−0.4 to 0.6) | |
| Duration (calendar days) among survivors, mean (SD) | 16.5 (9.9) | 16.3 (10.4) | 14.1 (10.4) | −0.2 (−0.8 to 0.5) | |
| Duration (calendar days) among nonsurvivors, mean (SD) | 9.6 (6.3) | 9.7 (6.6) | 9.2 (7.1) | 0.1 (−0.4 to 0.6) | −0.4 (−1.0 to 0.1) |
Definition of abbreviations: APACHE II = Acute Physiology and Chronic Health Evaluation; CI = confidence interval; COVID-19 = coronavirus disease; CPR = cardiopulmonary resuscitation; IQR = interquartile range; KDIGO = Kidney Disease: Improving Global Outcomes.
The 95% CIs were calculated using an exact formula for the difference in proportions, t-statistics for the difference in means, and the Bonett-Price formula for the difference in medians. The bold indicates P < 0.05. Analyses were based on observed data (not imputed).
See text for definitions.
Any severe comorbidities are defined as cardiovascular (symptoms of fatigue, claudication, dyspnea, or angina at rest), respiratory (shortness of breath with light activity or home ventilation), renal (receipt of renal replacement therapy for end-stage renal disease), liver-related (biopsy-proven cirrhosis, portal hypertension, or hepatic encephalopathy), metastatic disease–related (distant metastases), hematological malignancy–related (acute or chronic leukemia, multiple myeloma, or lymphoma), and immunocompromise–related (receipt of chemotherapy, radiotherapy, or daily high-dose steroid treatment in previous 6 months, HIV/AIDS, or a congenital immune deficiency).
Seventy-fifth percentile selected to illustrate changes in distribution over time.
Survivorship was calculated, and durations were capped at 28 days.
Figure 5.Adjusted 28-day in-hospital mortality, by time period and geography. The estimates represent the average marginal predicted risk of 28-day mortality for a patient with the mean values for all covariates, fitted after a multiple logistic regression. The results were adjusted for age, sex, ethnicity, quintile of deprivation, body mass index, any dependency before hospital admission, immunocompromised, sedated for entire of first 24 hours, highest temperature, lowest systolic blood pressure, highest heart rate, highest respiratory rate, PaO/FiO ratio, highest blood lactate concentration, highest serum creatinine, highest serum urea, lowest Hb concentration, and lowest platelet count. CI = confidence interval.